News & Updates
Filter by Specialty:
Saliva biomarkers can help predict diabetic neuropathy in type 1 diabetes
Salivary levels of the inflammatory biomarker immunoglobulin A (IgA) appear to be significantly suppressed in type 1 diabetes mellitus (DM) patients with neuropathy (DMN), reports a recent study.
Saliva biomarkers can help predict diabetic neuropathy in type 1 diabetes
21 Jul 2022
Tirzepatide beneficial for shedding pounds in obese adults
Once-weekly treatment with tirzepatide in adults with obesity appears to yield substantial and sustained reductions in body weight, according to the phase III SURMOUNT-1 trial.
Tirzepatide beneficial for shedding pounds in obese adults
21 Jul 2022
Chronic hepatitis C tied to cardiovascular events in T2DM
In patients with type 2 diabetes mellitus (T2DM), chronic hepatitis C and fatty liver appear to worsen the risk of cardiovascular events, a recent Taiwan study has found.
Chronic hepatitis C tied to cardiovascular events in T2DM
19 Jul 2022
Resmetirom demos potential in NASH
Safety analysis of the phase III MAESTRO-NAFLD-1 trial presented at ILC 2022 demonstrated the potential of resmetirom as a treatment for patients with non-alcoholic steatohepatitis (NASH) who have liver fibrosis.
Resmetirom demos potential in NASH
18 Jul 2022
Serum CTRP4 tied to coronary artery disease in T2DM
In patients with type 2 diabetes mellitus (T2DM), higher serum levels of circulating C1q tumour necrosis factor-related protein 4 (CTRP4) appear to aggravate the likelihood of coronary artery disease, a recent study has found.